ATE192338T1 - Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen - Google Patents

Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen

Info

Publication number
ATE192338T1
ATE192338T1 AT93913731T AT93913731T ATE192338T1 AT E192338 T1 ATE192338 T1 AT E192338T1 AT 93913731 T AT93913731 T AT 93913731T AT 93913731 T AT93913731 T AT 93913731T AT E192338 T1 ATE192338 T1 AT E192338T1
Authority
AT
Austria
Prior art keywords
pct
natural killer
killer cells
pharmaceutical preparation
date
Prior art date
Application number
AT93913731T
Other languages
English (en)
Inventor
Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Application granted granted Critical
Publication of ATE192338T1 publication Critical patent/ATE192338T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93913731T 1992-06-03 1993-06-03 Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen ATE192338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201719A SE513429C2 (sv) 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
PCT/SE1993/000496 WO1993024144A1 (en) 1992-06-03 1993-06-03 PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY

Publications (1)

Publication Number Publication Date
ATE192338T1 true ATE192338T1 (de) 2000-05-15

Family

ID=20386405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93913731T ATE192338T1 (de) 1992-06-03 1993-06-03 Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen

Country Status (12)

Country Link
US (1) US5728378A (de)
EP (1) EP0652768B1 (de)
JP (1) JP2888259B2 (de)
AT (1) ATE192338T1 (de)
CA (1) CA2136952C (de)
DE (1) DE69328558T2 (de)
DK (1) DK0652768T3 (de)
ES (1) ES2147758T3 (de)
GR (1) GR3033894T3 (de)
PT (1) PT652768E (de)
SE (1) SE513429C2 (de)
WO (1) WO1993024144A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063373A (en) 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
US6003516A (en) * 1992-06-03 1999-12-21 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
ATE241359T1 (de) * 1993-03-26 2003-06-15 Beth Israel Hospital Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
JPH10504304A (ja) * 1994-08-08 1998-04-28 マキシム ファーマシューティカルズ，インコーポレイテッド ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
IL141627A0 (en) * 1998-08-24 2002-03-10 Maxim Pharm Inc Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents
EP0998923A1 (de) * 1998-10-30 2000-05-10 Basf Aktiengesellschaft Verwendung von 5-HT7 Rezeptoragonisten zur Behandlung oder Vorbeugung von Ischämien
US6403806B1 (en) 1998-12-23 2002-06-11 Maxim Pharmaceuticals, Inc. Synthesis of histamine dihydrochloride
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6153113A (en) * 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
JP2005510501A (ja) * 2001-10-19 2005-04-21 マキシム ファーマシューティカルス，インコーポレイテッド 肝臓疾患治療へのヒスタミンの使用
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
US20050171192A1 (en) * 2003-12-11 2005-08-04 Gehlsen Kurt R. Use of histamine to treat bone disease
WO2006009975A2 (en) * 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
EP1712634A1 (de) * 2005-04-13 2006-10-18 Wittycell SAS Verfahren zur Auswahl von effizienten antigen präsentierenden Zellen und ihre Anwendung in der Regulation der Immunität
SG166716A1 (en) 2009-05-14 2010-12-29 Hsiehs Biotech Singapore Pte Ltd Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
CN115925920B (zh) * 2022-08-04 2023-07-25 瑞因细胞工程科技(广州)有限公司 一种基因增强型免疫细胞治疗肝硬化的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
EP0295317A1 (de) * 1987-06-16 1988-12-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Pharmazeutische Zusammensetzung zur Behandlung von Tumoren
US4883661A (en) * 1987-10-09 1989-11-28 Daly John M Use of arginine as an lymphokine synergist
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
EP0652768A1 (de) 1995-05-17
PT652768E (pt) 2000-09-29
DK0652768T3 (da) 2000-08-07
SE9201719D0 (sv) 1992-06-03
SE513429C2 (sv) 2000-09-11
GR3033894T3 (en) 2000-11-30
ES2147758T3 (es) 2000-10-01
EP0652768B1 (de) 2000-05-03
US5728378A (en) 1998-03-17
CA2136952A1 (en) 1993-12-09
JP2888259B2 (ja) 1999-05-10
SE9201719L (sv) 1993-12-04
JPH08502024A (ja) 1996-03-05
AU672610B2 (en) 1996-10-10
DE69328558T2 (de) 2001-01-04
WO1993024144A1 (en) 1993-12-09
AU4366093A (en) 1993-12-30
DE69328558D1 (de) 2000-06-08
CA2136952C (en) 2005-08-09

Similar Documents

Publication Publication Date Title
ATE192338T1 (de) Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen
RU2214418C2 (ru) Аналоги glp-1
ATE179429T1 (de) Cytokine dämpfende substanzen
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
BR0016227A (pt) Derivados de adamantano
DE69309712D1 (de) Pharmazeutische und dermokosmetische mittel enthaltend pferdecolostrum
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
PT99513A (pt) Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
DE69506007D1 (de) Transdermales system zur gleichzeitigen verabreichung von mehreren wirkstoffen
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
DE59406938D1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
ATE154235T1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
EP0173664A3 (de) Biologisch aktive Benzimidazolderivate und Verfahren zu ihrer Herstellung
ES2083167T3 (es) Sistemas de retardo mejorados para la liberacion retardada temporalmente de substancias de valor medico y/o biologico a partir de un material soporte de deposito.
PL315127A1 (en) Deuterised biologically active substances for percutaneous administration
AU666422B2 (en) Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds
NO944214L (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
NZ234451A (en) Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions
ATE169021T1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel
DK0817643T3 (da) Forbindelser og præparater til administration af aktive midler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee